Date: 2016-03-16
Type of information: Services contract
Compound: Ixiaro®
Company: Valneva (France- Austria) U.S.Department of Defense (USA)
Therapeutic area: Infectious diseases
Type agreement: services contract
Action mechanism:
Disease: Japanese encephalitis
Details: * On March 16, 2016, Valneva announced the signing of a $42 million contract with the US Government’s Department of Defense for the supply of its Japanese encephalitis (JE) vaccine Ixiaro®. Under the terms of the agreement, Valneva will supply Ixiaro® doses to the Defense Logistics Agency (DLA), Supply Center of the US Department of Defense for a total value of $42 million over a two-year period (a base year and an option year). First deliveries are expected to commence in the coming weeks.
Valneva’s Japanese encephalitis vaccine is indicated for active immunization for the prevention of Japanese encephalitis for adults who travel to, or live in, endemic areas. It has received marketing approval in the U.S., Europe, Canada, Hong Kong, Singapore, and Israel under the trade name Ixiaro® and in Australia and New Zealand where it is marketed as Jespect®. It is the only vaccine being marketed to the U.S. military for Japanese encephalitis.
Financial terms:
Latest news:
